Gemcitabine and taxanes in metastatic breast cancer: A systematic review

Therapeutics and Clinical Risk Management

Volumn 4, Issue 6, 2008, Pages 1157-1164

  Gudena, Vinay ^a   Montero, Alberto J ^a   Glück, Stefan ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Gemcitabine; Metastatic breast cancer; Taxanes

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; GEMCITABINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; BACKACHE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; EYE BURN; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; LOADING DRUG DOSE; LOW DRUG DOSE; METASTASIS POTENTIAL; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PORT SIDE INFECTION; PORT SIIE INFECTION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 61549099055     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Albain KS, Nag SM, Calderillo-Ruiz G, et al. 2008. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol, 26:3950-7.
2. Beslija S, Obralic N, Basic H, et al. 2006. Randomized trial of sequence vs combination of capecitabine (X) and docetaxel (T): XT vs T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts), 24:571.
3. Chan S, Romieu G, Houber J et al. 2005. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study. J Clin Oncol, 2005 ASCO Annu Meeting Proc 23(June 1 Suppl):581.
4. Citron ML, Berry DA, Cirrincione C, et al. 2003. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 21:1431-9.
5. Colomer R, Llombart-Cussac A, Lluch A, et al. 2004. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol, 15:201-6.
6. Delfino C, Caccia G, Gonzales LR, et al. 2004. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology, 66:18-23.
7. Fornier M, Norton L. 2005. Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res, 7:64-9.
8. Fountzilas G, Christodoulou C, Tsavdaridis D, et al. 2004. Paclitaxel and gemcitabine, as first-line, chemotherapy, combined with trastuzumab inpatients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest, 22:655-62.
9. Fumoleau P, Romieu G, Chan S, et al. 2006. Impact of symptoms and toxicity on quality of life: Exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. J Clin Oncol, 2006 ASCO Annu Meeting Proc 24(June 20 Suppl):682.
10. Gluck S, Lobo S, Reis I, et al. 2008. Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC). J Clin Oncol, 26(May 20 Suppl):Abstr 1089.
11. Huang P, Chubb S, Hertel LW, et al. 1991. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res, 51:6110-17.
12. Jemal A, Siegel R, Ward E, et al. 2008. Cancer statistics. CA Cancer J Clin, 58:71-96.
13. Khoo K-S MZ, Srimuninnimit V, Jiang ZF, et al. 2004. Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC). J Clin Oncol, 2004 ASCO Annu Meeting Proc 22(July 15 Suppl):710.
14. Kornek GV, Haider K, Kwasny W, et al. 2002. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res, 8:1051-6.
15. Kroep JR, Giaccone G, Tolis C, et al. 2000. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer, 83:1069-76.
16. Lobo C, Lopes G, Silva O, Gluck S. 2007. Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomed Pharmacother, 61:531-3.
17. Lück H-J dBA, Schrader I, Huober J, et al. 2007. Final results of the AGO Breast Cancer Study Group MAMMA-3 Trial: first-line capecitabine + paclitaxel vs epirubicin + paclitaxel for high-risk metastatic breast cancer. San Antonio Breast Cancer Symposium (SABCS). San Antonio.
18. Martin M, Ruiz A, Munoz M, et al. 2007. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol, 8:219-25.
19. Mavroudis D, Malamos N, Polyzos A, et al. 2004. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. Oncology, 67:250-6.
20. Miller K, Wang M, Gralow J, et al. 2007. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 357:2666-76.
21. Mompour C WJ, Donaldson G, Liepa A, et al. 2004. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study. J Clin Oncol, 2004 ASCO Annu Meeting Proc 22(July 15 Suppl):621.
22. Moreno-Aspitia A, Perez EA. 2005. North Central Cancer Treatment Group N0531. Phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin Breast Cancer, 6:361-4.
23. Murad AM, Guimaraes RC, Aragao BC, et al. 2001. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. Am J Clin Oncol, 24:264-8.
24. O'Shaughnessy J, Miles D, Vukelja S, et al. 2002. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol, 20:2812-23.
25. Pelegri A, Calvo L, Mayordomo JI, et al. 2002. Gemcitabine and docetaxel given every 2 weeks as first-line therapy for metastatic breast cancer (MBC): results of a GEICAM phase II study. Proc Am Soc Clin Oncol, 21:Abstr 1950.
26. Pelegri A, Calvo L, Anton A, et al. 2005. Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial. Clin Breast Cancer, 6:433-8.
27. Plunkett W, Huang P, Xu YZ, et al. 1995. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol, 22(4 Suppl 11):3-10.
28. Rossi D, Alessandroni P, Catalano V, et al. 2007; Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Clin Breast Cancer, 7:857-60.
29. Roy V, LaPlant BR, Gross GG, et al. 2007. NCCTG phase II trial N0531 of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer. Proc Am Soc Clin Oncol, 25(Suppl 18): A1048.
30. Silvestris N, Cinieri S, La Torre I, et al. 2008. Role of gemcitabine in metastatic breast cancer patients: A short review. Breast, 17:220-6.
31. Slamon DJ, Leyland-Jones B, Shak S, et al. 2001; Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344:783-92.
32. Sledge GW, Neuberg D, Bernardo P, et al. 2003. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol, 21:588-92.
33. Stinchcombe TE, Socinski MA, Lee CB, et al. 2008. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J Thorac Oncol, 3:521-6.
34. Theodossiou C, Cook JA, Fisher J, et al. 1998. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol, 12:825-32.
35. Zoli W, Ricotti L, Barzanti F, et al. 1999; Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer, 80:413-6.